Protagonist Therapeutics Inc PTGX

US Biotechnology

$140.97 ▼ -1.03% ($-1.47)

Open $143.45

Prev Close $142.44

Day Range $138.88 – $144.09

52W Range $62.24 – $160.81

Market Cap $9.12B

P/E (TTM) 109.23

Beta 1.18

EPS (TTM) $1.04

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2016-08-11
Shares Out.	64,310,000
Website	protagonist-inc.com/ ↗
Phone	13026365401
Employees	141
Revenue	$213.5M
Gross Profit	$213.5M
Net Income	$162.8M
Total Assets	$885.5M
Total Liabilities	$44.0M
Equity	$841.5M

About Protagonist Therapeutics Inc

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Protagonist Therapeutics Inc is a publicly traded company under the ticker symbol PTGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.